GlassScriptPhysician profile
Claudia A Clancy
NPI 1316271661
$3,057.27
in general payments reported to CMS, 2019-2025
34 companies · $611 in 2025
The $611 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.56 · 2022: $601 · 2023: $572 · 2024: $1,254 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,262 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.31 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $343.62 | 2022-2024 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $323.67 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $299.83 | 2022-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $250.43 | 2022-2024 | Enhertu, Calquence |
| Daiichi Sankyo INC. | $220.96 | 2024 | Enhertu |
| Pfizer INC. | $166.41 | 2024-2025 | |
| Abbvie INC. | $155.26 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $133.42 | 2024-2025 | Opdivo |
| Sobi, INC | $119.05 | 2023 | |
| Jazz Pharmaceuticals INC. | $102.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $97.46 | 2023-2025 | Keytruda, Welireg |
| Astellas Pharma US INC | $84.55 | 2024-2025 | Vyloy |
| Janssen Biotech, INC. | $84.11 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $74.13 | 2022-2025 | Fruzaqla, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $64.35 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $63.92 | 2022-2025 | Lynozyfic, Libtayo |
| Emd Serono, INC. | $61.03 | 2022-2024 | Tepmetko |
| Karyopharm Therapeutics INC. | $43.04 | 2023-2024 | Xpovio |
| Genentech USA, INC. | $41.15 | 2022-2025 | Itovebi |
| Gilead Sciences, INC. | $37.19 | 2023-2025 | Trodelvy |
| Adaptive Biotechnologies Corporation | $29.50 | 2023 | Clonoseq |
| Stemline Therapeutics INC. | $28.48 | 2025 | Orserdu |
| Genmab U.S., INC. | $26.07 | 2025 | Epkinly |
| Pharmaessentia USA Corporation | $24.13 | 2022 | |
| Epizyme, INC. | $22.98 | 2022 | |
| Celgene Corporation | $21.02 | 2023 | Opdualag |
| Eisai INC. | $21.00 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $19.13 | 2025 | Sancuso |
| Ipsen Biopharmaceuticals, INC | $18.56 | 2021 | |
| Seagen INC. | $17.95 | 2023 | Padcev |
| Array Biopharma INC | $17.46 | 2025 | Xalkori, Lorbrena, Braftovi |
| Agios Pharmaceuticals, INC. | $15.26 | 2023 | Pyrukynd |
| Secura Bio, INC. | $14.79 | 2024 | Copiktra |
| Puma Biotechnology, INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Clancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.